Somatostatin 2 receptor (sst2), deoxycytidine kinase (dck) and uridine monophosphate kinase (umk) pancreatic gene therapy
US9364494B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 10, 2008 |
| Grant date | Jun 14, 2016 |
| Priority date | — |
| Expiry date | Oct 21, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/04022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.